XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation
 6 Months Ended
Jul. 29, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The stock-based compensation costs that have been charged against income were as follows (in thousands):

13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Stock-based compensation expense by type:
Stock options
$— $— $220 $155 
Restricted stock units1,268 1,488 2,921 3,613 
Employee stock purchases
83 77 189 235 
Director deferred compensation26 24 52 41 
  Total stock-based compensation expense1,377 1,589 3,382 4,044 
Income tax benefit recognized263 369 649 926 
  Stock-based compensation expense, net of income tax$1,114 $1,220 $2,733 $3,118 

Expense for restricted stock units is shown net of forfeitures, which were immaterial for the 13-weeks and 26-weeks ended July 29, 2023 and July 30, 2022.
We granted the following equity awards:
13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Stock options
— — 8,188 7,212 
Restricted stock unit awards
— 1,673 78,515 109,521 
Performance-based restricted stock unit awards
— — 39,567 49,978 
Deferred stock units
705 532 1,155 937 

At July 29, 2023, the total compensation cost not yet recognized related to unvested restricted stock unit awards was $8.6 million and the weighted-average period over which such awards are expected to be recognized was 1.1 years. There were no unrecognized compensation costs related to unvested stock options at July 29, 2023.

Details of stock options granted, exercise price per share and the weighted-average grant date fair value were as follows:

13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Total stock options granted— — 8,188 7,212 
Exercise price$— $— $58.38 $46.22 
Fair value of stock options$— $— $26.87 $21.46 
Under the Hibbett, Inc. Amended and Restated Non-Employee Director Equity Plan, 10,469 shares of our common stock were subject to awards granted during the 26-weeks ended July 29, 2023 and 6,388 shares of our common stock were awarded during the 26-weeks ended July 30, 2022.
The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:
13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Shares purchased9,705 7,352 16,731 21,625 
Average price per share$30.85 $36.07 $38.95 $52.62 
Weighted-average fair value at grant date$15.18 $10.65 $16.19 $15.52